XOMA Royalty (XOMA) Cost of Revenue (2012 - 2013)
XOMA Royalty's (XOMA) quarterly Cost of Revenue came in at $21000.0 in Q2 2013, down 74.07% year-on-year from $81000.0 in Q2 2012, and down 54.35% quarter-over-quarter from $46000.0 in Q1 2013.
XOMA Royalty (XOMA) Cost of Revenue (2012 - 2013) Analysis & Trends
XOMA Royalty has disclosed Cost of Revenue across 2 years of filings, most recently posting $21000.0 for Q2 2013.
- Cost of Revenue for Q2 2013 came in at $21000.0, down 74.07% year-over-year; the trailing twelve-month figure through Jun 2013 was $128000.0 (up 58.02% YoY), and the FY2012 annual result was $143000.0, changed N/A from the prior year.
- Cost of Revenue came in at $21000.0 for Q2 2013 at XOMA Royalty, down from $46000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $81000.0 in Q2 2012 to a low of $21000.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 2.05 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 21,000.00 |
| Jun 30, 2013 | 21,000.00 |
| Mar 31, 2013 | 46,000.00 |
| Mar 31, 2013 | 46,000.00 |
| Dec 31, 2012 | 33,000.00 |
| Dec 31, 2012 | 33,000.00 |
| Sep 30, 2012 | 28,000.00 |
| Sep 30, 2012 | 28,000.00 |
| Jun 30, 2012 | 81,000.00 |
| Jun 30, 2012 | 81,000.00 |